69 related articles for article (PubMed ID: 1971785)
1. [Study of an MPTP-induced parkinsonian animal model in the rhesus monkey and the mechanism of the action of MPTP].
Chen S
Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1990 Feb; 23(1):23-6, 62. PubMed ID: 1971785
[TBL] [Abstract][Full Text] [Related]
2. D-deprenyl protects nigrostriatal neurons against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurotoxicity.
Muralikrishnan D; Samantaray S; Mohanakumar KP
Synapse; 2003 Oct; 50(1):7-13. PubMed ID: 12872288
[TBL] [Abstract][Full Text] [Related]
3. Study on MPTP-induced parkinsonian animal model in rhesus monkey and the mechanism of MPTP.
Chen SD; Xu DL; Yu HZ; Tang QM; Xu XR; Wang ZG; Liang PF
Chin Med J (Engl); 1988 Dec; 101(12):879-83. PubMed ID: 3150735
[No Abstract] [Full Text] [Related]
4. The actions of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in animals as a model of Parkinson's disease.
Jenner P; Marsden CD
J Neural Transm Suppl; 1986; 20():11-39. PubMed ID: 3091760
[TBL] [Abstract][Full Text] [Related]
5. [The effect of chronic treatment of deprenyl in animal models of Parkinson's disease].
Nakashima H; Asari S; Nishimoto A; Goldstein M
No To Shinkei; 1991 Apr; 43(4):357-61. PubMed ID: 1909537
[TBL] [Abstract][Full Text] [Related]
6. Neuroprotection of MPTP-induced toxicity in zebrafish dopaminergic neurons.
McKinley ET; Baranowski TC; Blavo DO; Cato C; Doan TN; Rubinstein AL
Brain Res Mol Brain Res; 2005 Nov; 141(2):128-37. PubMed ID: 16209898
[TBL] [Abstract][Full Text] [Related]
7. Characteristics of 1-methyl-4-(2'-methylphenyl)-1,2,3,6-tetrahydropyridine-induced neurotoxicity in the mouse.
Sonsalla PK; Youngster SK; Kindt MV; Heikkila RE
J Pharmacol Exp Ther; 1987 Sep; 242(3):850-7. PubMed ID: 2888874
[TBL] [Abstract][Full Text] [Related]
8. [Experimental research on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonian animal models in the rhesus monkey and C57 black mouse].
Chen S
Zhonghua Yi Xue Za Zhi; 1990 May; 70(5):252-4, 18. PubMed ID: 2168792
[TBL] [Abstract][Full Text] [Related]
9. Development of fluorinated 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine analogs with potent nigrostriatal toxicity for potential use in positron emission tomography studies.
Harik SI; Riachi NJ; Hritz MA; Berridge MS; Sayre LM
J Pharmacol Exp Ther; 1993 Aug; 266(2):790-5. PubMed ID: 8355208
[TBL] [Abstract][Full Text] [Related]
10. Selegiline and the prophylaxis of Parkinson's disease.
Sandler M; Willoughby J; Glover V; Gibb C
J Neural Transm Suppl; 1987; 25():35-43. PubMed ID: 3123604
[TBL] [Abstract][Full Text] [Related]
11. (-)Deprenyl in perspective: prophylaxis for Parkinson's disease?
Sandler M
J Neural Transm Suppl; 1986; 22():107-15. PubMed ID: 3097254
[TBL] [Abstract][Full Text] [Related]
12. [The effect of prolyl-leucyl-glycine (MIF-1) and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on dopamine levels of the striatum].
Sheng JG
Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1989 Aug; 22(4):213-5, 253. PubMed ID: 2575971
[TBL] [Abstract][Full Text] [Related]
13. Neuroprotective aspects of a novel MAO-B inhibitor PF9601N.
Pérez V; Morón J; Pastó M; Unzeta M
Neurobiology (Bp); 2000; 8(3-4):231-6. PubMed ID: 11225513
[TBL] [Abstract][Full Text] [Related]
14. Spinal cord degeneration in C57BL/6N mice following induction of experimental parkinsonism with MPTP.
Samantaray S; Knaryan VH; Butler JT; Ray SK; Banik NL
J Neurochem; 2008 Mar; 104(5):1309-20. PubMed ID: 18036149
[TBL] [Abstract][Full Text] [Related]
15. [A model of Parkinson's disease: effect of L-dopa therapy on movement parameters and electromyographic activity in monkeys treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)].
Doudet D; Gross C; Lebrun-Grandié P; Bioulac B
C R Seances Soc Biol Fil; 1985; 179(1):85-97. PubMed ID: 3161601
[TBL] [Abstract][Full Text] [Related]
16. Structure-activity study of the mechanism of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced neurotoxicity. I. Evaluation of the biological activity of MPTP analogs.
Youngster SK; Sonsalla PK; Sieber BA; Heikkila RE
J Pharmacol Exp Ther; 1989 Jun; 249(3):820-8. PubMed ID: 2786564
[TBL] [Abstract][Full Text] [Related]
17. [The bases of MPTP neurotoxicity].
Dostert P; Strolin Benedetti M
Encephale; 1988; 14(6):399-412. PubMed ID: 3068045
[TBL] [Abstract][Full Text] [Related]
18. Sympathetic innervation in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine primate model of Parkinson's disease.
Goldstein DS; Li ST; Holmes C; Bankiewicz K
J Pharmacol Exp Ther; 2003 Sep; 306(3):855-60. PubMed ID: 12805479
[TBL] [Abstract][Full Text] [Related]
19. The time course and magnitude of spontaneous recovery of parkinsonism produced by intracarotid administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine to monkeys.
Kurlan R; Kim MH; Gash DM
Ann Neurol; 1991 Jun; 29(6):677-9. PubMed ID: 1892370
[TBL] [Abstract][Full Text] [Related]
20. L-deprenyl confers specific protection against MPTP-induced Parkinson's disease-like movement disorder in the goldfish.
Adeyemo OM; Youdim MB; Markey SP; Markey CJ; Pollard HB
Eur J Pharmacol; 1993 Aug; 240(2-3):185-93. PubMed ID: 8243537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
